Robot-assisted radical prostatectomy versus volumetric modulated arc therapy: Comparison of front-line therapies for localized prostate cancer.
Robot-assisted radical prostatectomy versus volumetric modulated arc therapy: Comparison of front-line therapies for localized prostate cancer. Radiother Oncol. 2019 Jun 05;140:62-67 Authors: Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T, Nakagawa K, Abe O, Kume H, Fukuhara H Abstract BACKGROUND: Although radical prostatectomy and external beam radiotherapy are recognized as comparable treatment options for localized prostate cancer, robot-assisted radical prostatectomy (RARP) and volumetric modulated arc therapy (VMAT) as the leading respective techniques have yet to be compared. METHODS: We retrospectively analyzed 860 patients with cT1-4N0M0 prostate cancer who underwent RARP (n = 500) or VMAT (n = 360) between 2011 and 2016. Biochemical recurrence-free survival (bRFS; two consecutive prostate-specific antigen measurements ≥0.2 ng/ml for RARP and Phoenix definition for VMAT) and radiological recurrence-free survival (rRFS; radiologically diagnosed distant metastasis or local recurrence) were compared between the two modalities. Cox proportional hazards model was used for multivariate analysis. RESULTS: The median follow-up durations were 30 and 47.5 months, and median ages were 67 and 71 years (both P
We report our institution's high-volume experience and the most mature data to date on outcomes with 131Cs prostate BT.
Conditions: Prostate Cancer; Non-metastatic Prostate Cancer; Prostate Adenocarcinoma Interventions: Procedure: Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]; Procedure: Focal therapy; Procedure: Focal therapy after Finasteride 5Mg tablets for 12 weeks; Procedure: Focal therapy after Bicalutamide 50Mg tablets for 12 weeks Sponsors: Imperial College London; Prostate Cancer UK; Imperial Clinical Trials Unit (ICTU) Not yet recruiting
Conclusion: RP patients with low PSA levels and high GS had better OS compared to either EBRT or EBRT+BT, while RP and EBRT+BT resulted in significantly lower PCSM, compared to EBRT. Moreover, EBRT+BT and RP were associated with similar survival of patients with age of> 70 years old, or PSA levels of ≤ 2.5 ng/ml.
In this study we evaluate the lesion detection efficacy of18F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value.MethodsA total of 248 consecutive patients were evaluated and underwent scanning with18F-DCFPyL PET/CT for BCR between November 2016 and 2018 in two hospitals in the Netherlands. Patients were examined after radical prostatectomy (52%), external-beam radiation therapy (42%) or brachytherapy (6%). Imaging was performed 120 min after injection of a median dose of 311 MBq18F-DCFPyL.ResultsIn 214 out of 248 PET/CT scans (86.3%), at least one lesion sug...
CONCLUSIONS: In this systematic review and meta-analysis, we did not observe higher rate of BCR after TRT for nonmetastatic CaP patients after definitive local therapy. Based on these data, others and we have outlined a phase I/II trial assessing the safety and benefits of TRT in select men with secondary symptomatic hypogonadism who have no active disease after definitive local CaP therapy with curative intent. PMID: 31296421 [PubMed - as supplied by publisher]
Publication date: Available online 4 June 2019Source: European UrologyAuthor(s): Sebastian Berg, Alexander Cole, Quoc-Dien Trinh
FDA has given approval for AngioDynamics to undergo a pilot study of the NanoKnife for the ablation of prostate cancer tissue in low-risk patients. The IDE comes on the heels of the Latham, NY-based company making significant strides in its mission to obtain an indication for the treatment of pancreatic cancer. âNanoKnife has been in the market for a general soft tissue claim for about eight or nine years,â Brent Boucher, AngioDynamics, Senior VP and General Manager of Oncology, told MD+DI. âOn April 1 we received approval to pursue a pancreas indication for stage three...
Publication date: Available online 23 May 2019Source: European UrologyAuthor(s): Michael Froehner, Christian Thomas